Tue, Sep 16, 2014, 12:16 AM EDT - U.S. Markets open in 9 hrs 14 mins


% | $
Quotes you view appear here for quick access.

Ford Motor Co. Message Board

eliapostchild 3 posts  |  Last Activity: 10 hours ago Member since: Jan 26, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • eliapostchild eliapostchild 10 hours ago Flag

    1:4 reverse split in december 2012.

  • bad pun attempt...but another Pfizer connection...hmmm...

    Published: Aug 19, 2014 8:54 a.m. ET

    HEADLINE2Turns to a marketing wizard behind Viagra and Celebrex to commercialize its MRX technology

    ALBUQUERQUE, N.M., Aug 19, 2014 (BUSINESS WIRE) -- Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics (otcqb:MHTX). Mr. Falk previously held senior marketing positions at Pfizer and Forest Laboratories, and has had a 35-year career in the pharmaceutical and diagnostic sector fields.

    Gerald Grafe, president of Senior Scientific, commented, “We’re in the rapid, early-detection business, and the fastest way we know for top corporate partners to detect us is via Mr. Falk’s sterling position in the medical device and pharmaceutical industry.” Spencer Falk’s personal contacts include senior management professionals leading oncology product development at firms including Merck, Astra-Zeneca/Medimmune, Pfizer, Esai, Johnson & Johnson and others. Mr. Falk will replace Loraine Upham.

    Mr. Falk had been responsible for introducing Senior Scientific to the key oncology researchers at the MD Anderson Cancer Research Hospital, which led to their undertaking validation studies. MD Anderson received and is testing Senior Scientific’s first early-detection device (called “MRX”). The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known.

  • Reply to

    OPXA mkt cap really really cheap imo

    by apfappa Jul 29, 2014 3:09 PM
    eliapostchild eliapostchild Aug 6, 2014 4:52 PM Flag

    small company (mkt cap ~$42M), low float, important drug, little coverage or press. any news on Tcelna will move the PPS dramatically. spend some time on the website -- they release excellent presentations describing Tcelna. limited analyst coverage, but i've seen a price target in the $4-6 range.

16.47-0.12(-0.72%)Sep 15 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT